Drugs / AD17002
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05985694 | Nov 2023 → Jan 2025 | — | Advagene Biopharma Co. Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT05069610 | Mar 2022 → Oct 2023 | COVID-19 | Advagene Biopharma Co. Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04088721 | Mar 2019 → Jul 2020 | allergic rhinitis | Advagene Biopharma Co. Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07250594 | Dec 2025 → Oct 2026 expected | T2-high asthma | Advagene Biopharma Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05541510 | Dec 2022 → Aug 2024 | COVID-19 | Advagene Biopharma Co. Ltd. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD17002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05541510 ↗ |
| Known as | LTh(αK) | “The AD17002, also known as LTh(αK), is an immunomodulator” NCT05069610 ↗ |
| Modality | Protein / enzyme biologic | “A recombinant protein” NCT05069610 ↗ |
| Route | Intranasal | “Intranasal weekly dosing of AD17002 for three times” NCT04088721 ↗ |